Comunicati Stampa
Elettronica

Okmetic focuses on its core business and closes down its epi plant in the United States

OKMETIC OYJ        STOCK EXCHANGE RELEASE     9 DECEMBER 2015       AT 8.00 A.M. OKMETIC FOCUSES ON ITS CORE BUSINESS AND CLOSES DOWN ITS EPI PLANT IN THE UNITED STATES Okmetic has decided to phase out of its epitaxial deposition business and close down its Allen plant located in the United States that is focused on epitaxial deposition of silicon wafers. The facility will be wound down gradually by the end of 2016...
New York, (informazione.news - comunicati stampa - elettronica)

 

Okmetic has decided to phase out of its epitaxial deposition business and close down its Allen plant located in the United States that is focused on epitaxial deposition of silicon wafers. The facility will be wound down gradually by the end of 2016. The closure of the unit, which has become unprofitable, will improve the company's operating profit and cash flow after the wind-down, and will also free up capital for other key strategic projects.

 

"In accordance with its strategy, the company focuses on high value-added silicon wafers, which it supplies for the manufacture of sensors, discrete semiconductors and analog circuits. The aim is to increase the company's relative and absolute profitability in the long run, and the decision to close the Allen production facility is in line with this aim", says President Kai Seikku.

 

The long phase-out period will ensure that we are able to support customers through this transition. Changing to a new epi supplier can take up to a year, during which time the company wants to secure the operation of customer supply chains. Okmetic will do its very best to ensure that the wind-down of the plant impacts the customers as little as possible. The company draws up customer specific plans for supporting their business and helps them find alternative suppliers.

 

In connection with the wind-down of the plant, 3.0 million euro will be entered as non-cash impairment loss and provisions in the final quarter of 2015. Okmetic's outlook and financial guidance for 2015 remain unchanged .

 

Okmetic acquired the Allen plant in 1999. It further processes the silicon wafers manufactured at the company's plant in Vantaa, Finland by making an epitaxial deposition on the surface of the wafers. In 2014, the net sales of the Allen facility amounted to 11.1 million euro. The closure of the plant will affect 39 employees. The company will support them with redundancy packages and help them find new employment. The closure will not affect the organisation of US sales and customer support, which will continue at its present strength. Okmetic will continue to invest strongly in its growth and presence in the North American market.

 

"I want to thank the personnel of the Allen facility for their hard work and commitment to the company's goals over the years. I would like to thank our customers for the trust they have shown in the company. The closure of the plant is unfortunate but necessary since the prerequisites for profitable business are no longer fulfilled. As a result of the Allen plant closure, the company will be able to serve its customers better than ever in its core business", says Kai Seikku.

 

 

OKMETIC OYJ

 

Kai Seikku

President

 

 

For further information, please contact:

 

President Kai Seikku (from 2 p.m. EET onwards)

tel. +358 9 5028 0232, email: kai.seikku@okmetic.com

 

Senior Vice President, Finance, IT and Communications Juha Jaatinen

tel. +358 9 5028 0286, email: juha.jaatinen@okmetic.com

 

Senior Vice President, Customers and Markets Anna-Riikka Vuorikari-Antikainen

tel. +358 9 5028 0461, email: anna-riikka.vuorikari-antikainen@okmetic.com

 

 

 


Copyright GlobeNewswire

Attachment(s)
http://hugin.info/132025/R/1972244/721308.pdf

Regulatory News
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire



Per maggiori informazioni
Ufficio Stampa
 Thomson Reuters (Leggi tutti i comunicati)
3 Times Square
10036 New York, NY